Aeterna Zentaris to Announce First Quarter 2011 Financial and Operating Results and Hold Annual Shareholder Meeting on May 18, 2

QUEBEC CITY, May 11 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2011 financial and operating results before market open on Wednesday, May 18, 2011. The Company will host a conference call and webcast to discuss these results later that same day at 2:00 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the following numbers: in Canada 514-807-8791 or 416-644-3424, outside Canada, 877-974-0446. A replay of the webcast will also be available on the Company's website for a period of 30 days.

The Company further announced that it will hold its Annual Shareholder Meeting also on Wednesday, May 18, 2011 starting at 10:30 a.m. Eastern Time, in Rooms Jarry & Joyce of the Centre Sheraton Montreal Hotel, 1201 René-Lévesque Boulevard West, in Montreal.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.